• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Medicure Obtains Exclusive License for Cardiovascular Drug

    Bryan Mc Govern
    Dec. 14, 2017 09:43AM PST
    Pharmaceutical Investing

    Medicure announced its subsidiary Medicure International it acquired the exclusive licensing rights of an undisclosed recently approved cardiovascular drug in the US.

    Medicure (TSXV:MPH; OTC:MCUJF) announced its subsidiary Medicure International it acquired the exclusive licensing rights of an undisclosed recently approved cardiovascular drug in the US.
    As quoted in the press release:

    The licensing agreement is for a term of seven years with extensions to the term available.

    The cardiovascular drug was approved earlier in 2017 by the U.S. Food and Drug Administration (“FDA”) for sale and marketing in the United States and the Company intends to launch the product using its existing commercial sales force and infrastructure with a target commercial launch date in the first half of 2018.

    “This licensing agreement, similar to our recent licensing of PREXXARTAN, fits well with Medicure’s mission of being a significant cardiovascular pharmaceutical company focused on the U.S. market,” commented Medicure’s President and CEO, Dr. Albert D. Friesen.

    Click here to read the full press release.

    Source: www.newswire.ca

    pharmaceutical investinglicensing agreementunited statesfood and drug administration
    The Conversation (0)

    Go Deeper

    AI Powered
    Medical pills branded with Canadian flag.

    Canadian Pharma Stocks: 5 Biggest Companies

    Illustration of heart attack.

    Investing in Cardiovascular MedTech Companies

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×